TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2456618

Group type: COMPARATOR
Intervention: Watch and wait (limited RT if necessary)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aggressive combined modality treatment (ProMACE-MOPP + TNI)
Number of subjects: 104
Study: 25039577

Group type: EXPERIMENTAL
Intervention: Oral B CrossAction Power electric toothbrush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Bitufo Class 32 soft toothbrush
Number of subjects: 60
Study: 31189280

Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-pacifier use
Number of subjects: 28
Study: 29313577

Group type: EXPERIMENTAL
Intervention: Risorine (Rifampicin 200 mg + Isoniazid 300 mg + Piperine 10 mg)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional anti-TB therapy
Number of subjects: 216
Study: 25450635

Group type: EXPERIMENTAL
Intervention: Interferon alpha (one subcutaneous injection/week for 4 weeks) in addition to standard protocol therapy (systemic pulse corticosteroids/cyclophosphamide with sulphasalazine and pentoxifylline)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard protocol therapy (systemic pulse corticosteroids/cyclophosphamide with sulphasalazine and pentoxifylline)
Number of subjects: 30
Study: 22921686

Group type: EXPERIMENTAL
Intervention: Computerized counseling about contraceptive options and screening for contraindications
Number of subjects: 814

Group type: COMPARATOR
Intervention: Control group (no computerized counseling)
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Computerized counseling
Number of subjects: 814
Study: 21688900

Group type: EXPERIMENTAL
Intervention: $1,000 increase in annual family income
Number of subjects: 0
Study: 18239394

Group type: EXPERIMENTAL
Intervention: Biphasic shocks (50 Joules)
Number of subjects: 95
Study: 16869919

Group type: EXPERIMENTAL
Intervention: Specific, constructive feedback on knot-tying skill
Number of subjects: 33

Group type: COMPARATOR
Intervention: General compliments
Number of subjects: 33
Study: 12923649

Group type: EXPERIMENTAL
Intervention: Diet containing partially hydrogenated fat (5.6% of energy)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diet high in palmitic acid (10.6% of energy)
Number of subjects: 10
Study: 11203827

Group type: EXPERIMENTAL
Intervention: Tetric (composite, Group A: n = 36)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dyract (compomer, Group B: n = 79)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fuji II LC (resin-modified glass ionomer cement, Group C: n = 51)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Photac-Fil (resin-modified glass ionomer cement, Group D: n = 31)
Number of subjects: 37
Study: 9310601

Group type: EXPERIMENTAL
Intervention: Homoeopathy
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Homoeopathy (good-quality studies)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Homoeopathy (corrected for publication bias)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Homoeopathy (single remedy for seasonal allergies)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Homoeopathy (postoperative ileus)
Number of subjects: 119
Study: 7508742

Group type: EXPERIMENTAL
Intervention: L-thyroxine tablet (150 micrograms)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: L-thyroxine solution (150 micrograms)
Number of subjects: 14
Study: 3712166

Group type: EXPERIMENTAL
Intervention: High medium-chain triglyceride (MCT) formula
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low medium-chain triglyceride (MCT) formula
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High MCT formula
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low MCT formula
Number of subjects: 15
Study: 30167644

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 600 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 26259519

Group type: EXPERIMENTAL
Intervention: GS‐4997 (apoptosis signal‐regulating kinase 1 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23514876

Group type: EXPERIMENTAL
Intervention: Full ROM isolated lumbar extension exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Limited ROM isolated lumbar extension exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 21931019

Group type: EXPERIMENTAL
Intervention: TASQ 0.25 mg/d escalating to 1.0 mg/d over 4 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: TASQ
Number of subjects: 201
Study: 18248654

Group type: EXPERIMENTAL
Intervention: Esomeprazole 80 mg intravenous bolus infusion for 30 min followed by esomeprazole 8 mg/h intravenously for 71.5 h
Number of subjects: 2008

Group type: COMPARATOR
Intervention: Placebo infusion for 72 h
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Esomeprazole 80 mg intravenous bolus infusion followed by esomeprazole 8 mg/h intravenously
Number of subjects: 2008
Study: 16449416

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy (IPT) plus pill‐placebo
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) plus citalopram (20 to 40 mg per day)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standardized clinical management (CM) plus pill‐placebo
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Standardized clinical management (CM) plus citalopram (20 to 40 mg per day)
Number of subjects: 280
Study: 12729356

Group type: EXPERIMENTAL
Intervention: Merlano chemo-radiotherapy
Number of subjects: 48
Study: 10589889

Group type: EXPERIMENTAL
Intervention: Colloids (dextran 70 or gelafundin 35,000)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 50

Group type: COMPARATOR
Intervention: Crystalloids (Ringer's lactate or 0.9%-weight/volume saline)
Number of subjects: 50
Study: 8739093

Group type: EXPERIMENTAL
Intervention: Dipyrone 3 g/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dipyrone 1.5 g/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Paracetamol 1.5 g/day
Number of subjects: 36
Study: 1953218

Group type: EXPERIMENTAL
Intervention: Computerized impedance plethysmography (CIP)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Computerized impedance plethysmography (CIP) for proximal DVT
Number of subjects: 246
Study: 7008184

Group type: EXPERIMENTAL
Intervention: 0.44 g acetylsalicylic acid (ASA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3.96 g acetylsalicylic acid (ASA)
Number of subjects: 25
Study: 30550301

Group type: EXPERIMENTAL
Intervention: EC (intervention condition)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: CC (control condition)
Number of subjects: 1686
Study: 27692566

Group type: EXPERIMENTAL
Intervention: Final Kissing Balloon Technique (FKBT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Single-stent implantation without FKBT
Number of subjects: 108
Study: 26341393

Group type: EXPERIMENTAL
Intervention: AVD+ (audio and visual distraction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AVD- (non-distraction)
Number of subjects: 0
Study: 25675559

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with anti-hypertensive plaster
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 60
Study: 22409641

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 19450370

Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) supplementation (45 microg for 8 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 17596256

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 100
Study: 10812288

Group type: EXPERIMENTAL
Intervention: Trazodone (T)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Clonidine (C)
Number of subjects: 45
Study: 9092959

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 12
Study: 8251778

Group type: EXPERIMENTAL
Intervention: 5,6‐benzo‐alpha‐pyrone (200 mg tablets, two daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (two tablets daily)
Number of subjects: 104
Study: 2870876

Group type: EXPERIMENTAL
Intervention: 0.5 mg loprazolam
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 1.0 mg loprazolam
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 31757794

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Troglitazone treatment of cultured human adipocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 29733520

Group type: EXPERIMENTAL
Intervention: Mango consumption (300 g for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equivalent amount of fiber
Number of subjects: 0
Study: 28236989

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24161369

Group type: COMPARATOR
Intervention: Thin liquid barium (THIN)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Liquid barium thickened with a starch‐based agent (STARCH)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Liquid barium thickened with a gum‐based agent (GUM)
Number of subjects: 100
Study: 22055271

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 6x10^9
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 19965540

Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 40
Study: 18190615

Group type: EXPERIMENTAL
Intervention: Low-residue diet, placebo fibre supplement, and loperamide
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fibre supplement, neutral diet, and loperamide
Number of subjects: 63
Study: 15864137

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol treatment
Number of subjects: 206

Group type: COMPARATOR
Intervention: Family history of psoriasis
Number of subjects: 206
Study: 12645717

Group type: EXPERIMENTAL
Intervention: Combined system (heparin-coated, centrifugal pump, closed circuit)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional system (uncoated system, roller pump, hard shell venous reservoir)
Number of subjects: 40
Study: 10641539

Group type: EXPERIMENTAL
Intervention: Rehabilitation psychotherapy (including pathogenetic and symptomatic psychotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rehabilitation psychotherapy
Number of subjects: 0
Study: 8787184

Group type: EXPERIMENTAL
Intervention: Right hemisphere damage (RH-damaged group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Left hemisphere damage (LH-damaged group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 28
Study: 1804598

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g twice a day i.v.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once daily i.v.
Number of subjects: 72
Study: 30057058

Group type: EXPERIMENTAL
Intervention: Combination of Swedish massage and preferred music
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Swedish massage
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 26650825

Group type: EXPERIMENTAL
Intervention: Self-management program (abdominal massage, abdominal muscle stretching, education on proper defecation position)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control group (received the program before the second chemotherapy cycle)
Number of subjects: 30
Study: 24392491

Group type: EXPERIMENTAL
Intervention: Connective tissue graft (CTG) as a barrier
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bioresorbable collagen membrane (control)
Number of subjects: 20
Study: 23146636

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe pain during injection
Number of subjects: 25
Study: 20491987

Group type: EXPERIMENTAL
Intervention: One-visit root canal treatment (n = 43)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Two-visit root canal treatment (n = 46)
Number of subjects: 89
Study: 19253522

Group type: EXPERIMENTAL
Intervention: Combination therapy (80% of patients)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker monotherapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Diuretic monotherapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Monotherapy (20% of patients)
Number of subjects: 145
Study: 16012079

Group type: EXPERIMENTAL
Intervention: 20mg of racemic rabeprazole
Number of subjects: 16

Group type: COMPARATOR
Intervention: 30 mg of racemic lansoprazole
Number of subjects: 16
Study: 12945829

Group type: EXPERIMENTAL
Intervention: HMB (3 g/d)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HMBCr (3 g/d HMB, 3 g/d Cr)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 11012004

Group type: EXPERIMENTAL
Intervention: Sterile moisturizer and sterile cleanser used in combination, applied once or twice daily for 28 days
Number of subjects: 98
Study: 8711553

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (0.4 g/kg/day for 5 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (similar volume daily for 5 days)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2005562

Group type: EXPERIMENTAL
Intervention: Ultrasound anterior capsule cleaning
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intercapsular procedure without ultrasound cleaning
Number of subjects: 62
Study: 6195236

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-detergent
Number of subjects: 5536

Group type: COMPARATOR
Intervention: Non-medicated soap
Number of subjects: 5536
Study: 31352063

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT
Number of subjects: 31
Study: 28067075

Group type: EXPERIMENTAL
Intervention: Laparoscopic aortobifemoral bypass (LABF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open aortobifemoral bypass (OABF)
Number of subjects: 30
Study: 26462611

Group type: EXPERIMENTAL
Intervention: Slow chewing (50 chews min‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fast chewing (100 chews min‐1)
Number of subjects: 14
Study: 24464632

Group type: EXPERIMENTAL
Intervention: Combivir® (zidovudine [ZDV] + lamivudine [3TC]) + Aluvia® (lopinavir/ritonavir [LPV/RTV])
Number of subjects: 30
Study: 22011265

Group type: EXPERIMENTAL
Intervention: Clindamycin 40 mg/kg/24 h
Number of subjects: 252

Group type: COMPARATOR
Intervention: First-generation cephalosporin 150 mg/kg/24 h
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 252

Group type: COMPARATOR
Intervention: First-generation cephalosporin
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Clindamycin and first-generation cephalosporin
Number of subjects: 252
Study: 19545366

Group type: EXPERIMENTAL
Intervention: Intervention to optimise secondary prevention of coronary heart disease
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Recruitment strategy involving telephoning practices, posting information, visiting practices, identifying potential participants, posting invitations and obtaining consent
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Collaborative relationship between researcher and practice staff
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Monitoring progress within trials and tailoring strategies
Number of subjects: 903
Study: 17469676

Group type: EXPERIMENTAL
Intervention: Novel study design (randomized start or withdrawal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological markers
Number of subjects: 0
Study: 16089138

Group type: EXPERIMENTAL
Intervention: Fuzheng quxie granule (FQG) + conventional western medicine (WM)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional western medicine (WM) alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fuzheng quxie granule (FQG) alone
Number of subjects: 59
Study: 12029409

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study: 10206604

Group type: EXPERIMENTAL
Intervention: Treadmill walking with no body weight support
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treadmill walking with 15% body weight relief
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treadmill walking with 30% body weight relief
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treadmill walking (all conditions)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Floor walking
Number of subjects: 18
Study: 7843696

Group type: EXPERIMENTAL
Intervention: 28 weeks of natural IFN‐alpha treatment
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 52 weeks of natural IFN‐alpha treatment
Number of subjects: 88
Study: 2146903

Group type: EXPERIMENTAL
Intervention: 20 ml/kg compound sodium lactate solution
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 20 ml/kg compound sodium lactate solution + 1 g/kg dextrose
Number of subjects: 75
Study: 83088

Group type: EXPERIMENTAL
Intervention: 2% erythromycin base in hydroalcoholic solution + 0.05% tretinoin solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% tretinoin solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% erythromycin base in hydroalcoholic solution
Number of subjects: 0
Study: 29874199

Group type: EXPERIMENTAL
Intervention: LactoWise® (4.5 billion live cells of bacillus coagulans and galactomannans, 300 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (600 mg of calcium citrate yielding 126 mg of elemental calcium)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LactoWise®
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31864217

Group type: EXPERIMENTAL
Intervention: Exposure-based minimal-contact CBT (guided Internet-delivered CBT, unguided Internet-delivered CBT, bibliotherapy)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Exposure-based minimal-contact CBT
Number of subjects: 132

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 132
Study: 30428750

Group type: EXPERIMENTAL
Intervention: Active choice (the patient could choose the gender of the practitioner)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Same gender (female practitioner by default)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Control (practitioner's gender is unknown)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Opposite gender (male practitioner by default)
Number of subjects: 1060
Study: 28894361

Group type: EXPERIMENTAL
Intervention: 1,200 IU vitamin D3 per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25761469

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 0
Study: 23500237

Group type: EXPERIMENTAL
Intervention: Ranolazine (target dose 1000 mg bid)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study: 22340311

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS, transforaminal lumbar interbody fusion via MAST Quadrant retractor)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Open surgery (improved transforaminal lumbar interbody fusion)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 79
Study: 19699156

Group type: EXPERIMENTAL
Intervention: LEV XR (1000mg/day)
Number of subjects: 555
Study: 17461854

Group type: EXPERIMENTAL
Intervention: TMC114/r (600/100 mg bid)
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: TPV/r (500/200 mg bid)
Number of subjects: 1360

Group type: COMPARATOR
Intervention: CPI (Control)
Number of subjects: 1360

Group type: COMPARATOR
Intervention: TMC114/r vs CPI
Number of subjects: 1360

Group type: COMPARATOR
Intervention: TPV/r vs CPI
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: TMC114/r
Number of subjects: 1360
Study: 15351193

Group type: EXPERIMENTAL
Intervention: Tamoxifen (B-14, n=1439)
Number of subjects: 3682

Group type: EXPERIMENTAL
Intervention: CMFT (Cyclophosphamide, Methotrexate, Fluorouracil, and Tamoxifen) (B-20, n=789)
Number of subjects: 3682

Group type: COMPARATOR
Intervention: Placebo (B-14, n=1453)
Number of subjects: 3682

Group type: COMPARATOR
Intervention: Tamoxifen (B-20, n=788)
Number of subjects: 3682
Study: 12089852

Group type: EXPERIMENTAL
Intervention: Analgesic, hormonal, and surgical treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensory awareness-directed physiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural stress management intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible biopsychosocial approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empathic medical evaluation and follow-up
Number of subjects: 0
Study: 9642607

Group type: COMPARATOR
Intervention: gemeprost 1 mg 3 hourly for 5 doses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: misoprostol 200 mcg 6 hourly for 4 doses
Number of subjects: 100

Group type: COMPARATOR
Intervention: gemeprost
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: misoprostol
Number of subjects: 100
Study: 7661175

Group type: EXPERIMENTAL
Intervention: Nabumetone, 1 g, b.i.d.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Naproxen, 500 mg, b.i.d.
Number of subjects: 52
Study: 2504171

Group type: EXPERIMENTAL
Intervention: Recombinant human gamma-interferon (rHu gamma-IFN)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105